CLYM (Climb Bio) Ending Cash Position: $8.36 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLYM Climb Bio Inc CLYM
22 GF Score
Price $12.11
! 2 Warning Signs
View Full Analysis

What is Climb Bio Ending Cash Position?

Climb Bio CLYM -1.38% 22 Ending Cash Position is $8.36 Mil as of Mar. 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Climb Bio's Ending Cash Position for the quarter that ended in Mar. 2026 was $8.36 Mil.

Climb Bio's quarterly Ending Cash Position increased from Sep. 2025 ($25.80 Mil) to Dec. 2025 ($35.69 Mil) but then declined from Dec. 2025 ($35.69 Mil) to Mar. 2026 ($8.36 Mil).

Climb Bio's annual Ending Cash Position declined from Dec. 2023 ($93.11 Mil) to Dec. 2024 ($87.23 Mil) and declined from Dec. 2024 ($87.23 Mil) to Dec. 2025 ($35.69 Mil).

Climb Bio Ending Cash Position Related Terms

Climb Bio Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Climb Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Climb Bio Ending Cash Position Chart

Climb Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 46.92 43.59 93.11 87.23 35.69

Climb Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.02 22.68 25.80 35.69 8.36
CLYM
22GF Score
Climb Bio Inc CLYM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Climb Bio's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=87.229+-51.544
=35.69

Climb Bio's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=35.685+-27.329
=8.36

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $8.36 Mil mean?
Climb Bio (CLYM) has a Ending Cash Position of $8.36 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Climb Bio and its competitors.
Is Climb Bio's Ending Cash Position too high?
Climb Bio's current Ending Cash Position is $8.36 Mil. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Ending Cash Position compare to DSGN and MNPR?
Climb Bio's Ending Cash Position of $8.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Climb Bio and its competitors. Climb Bio's current Ending Cash Position is $8.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Ending Cash Position of $8.36 Mil. The current Ending Cash Position is $8.36 Mil. Climb Bio's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Climb Bio (CLYM), the current Ending Cash Position is $8.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.11
Price